JI-101 / Jubilant Pharmova - LARVOL DELTA

Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma. (PubMed, J Cell Mol Med) - "The use of two EPHB4 inhibitors, JI-101 and NVP-BHG712, was able to rescue the phenotype driven by the variant. Our study suggested that EPHB4 is a promising therapeutic target in high-risk NB."

Journal • Neuroblastoma • Oncology • Solid Tumor • ALK • CDK4 • EPHB4 • RAF1 • RET